Batilol exhibits a broad spectrum of bioactivities across various biological targets and cell lines. It effectively inhibits Bacillus subtilis Sfp phosphopantetheinyl transferase, ubiquitin-specific protease USP2a, malarial parasite plastid, and multiple human tumor cell lines including those from lung, renal, leukemia, melanoma, and ovarian cancers. It also shows potency in the inhibition of Schwann cell PMP22 intronic element firefly luciferase assay and displays stage-specific inhibition of Vaccinia Orthopoxvirus. Additionally, Batilol demonstrates activity in blocking the entry of Ebola Virus, indicating its potential antiviral properties.
The compound exhibits significant inhibition of sodium fluorescein uptake in OATP1B1- and OATP1B3-transfected CHO cells, with inhibition percentages of 92.94% and 108.34% at 10 µM, respectively. Furthermore, it shows antibacterial activity against multiple bacterial strains, including Klebsiella pneumoniae MDR, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus MRSA, and Acinetobacter baumannii, with varying degrees of inhibition. While its antifungal activity against Cryptococcus neoformans H99 is low, it shows no inhibitory effect against Candida albicans.
Moreover, Batilol demonstrates inhibitory effects on glycogen phosphorylase, glucose-6-phosphatase, and PTP1B, albeit with modest inhibition percentages. Notably, it binds to the recombinant human full-length N-GLY1 catalytic domain, as indicated by an increase in melting temperature and a Kd value of 221500.0 nM.
Overall, Batilol displays a wide range of bioactivities, making it a promising candidate for further investigation in various therapeutic areas..
Note: Summary generated by AI, AI may be wrong some times, we do not provide any medical advice and only sell our product to accredited institution, Please cross-check with other sources, data source: chembl 